A Comprehensive Review on Polymer-Lipid Hybrid Nanoparticles

An innovative drug delivery method called polymer-lipid hybrid nanoparticles (PLNs) blends the biomimetic qualities of lipid-based carriers with the structural advantages of polymeric nanoparticles. These hybrid nanoparticles are perfect for targeted therapeutics, such as gene delivery and cancer treatment, since they provide improved drug stability, bioavailability, and controlled release. PLNs are made up of an exterior PEGylated lipid layer to extend circulation, a lipid monolayer for stability, and a polymer core that encapsulates the medication. For particular therapeutic purposes, several varieties have been created, including erythrocyte membrane-camouflaged nanoparticles, monolithic PLNs, and polymer core lipid shells. High-pressure homogenization, emulsification-solvent evaporation, and nanoprecipitation are preparation techniques. Despite the fact that PLNs have several benefits, issues including batch-to-batch uniformity, large-scale production, and possible cytotoxicity still exist. Research is also being done to incorporate stimuli-responsive drug release mechanisms, optimize their design, and increase drug loading efficiency. PLNs offer better medication delivery with fewer adverse effects, making them a revolutionary technique in nanomedicine. These nanoparticles have enormous promise for next-generation pharmaceutical applications and personalized medicine with further development, guaranteeing safer and more efficient therapies.